Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 694,883,456
  • Shares Outstanding, K 950,164
  • Annual Sales, $ 34,124 M
  • Annual Income, $ 5,240 M
  • 60-Month Beta 0.34
  • Price/Sales 20.22
  • Price/Cash Flow 97.81
  • Price/Book 65.18
Trade LLY with:

Options Overview Details

View History
  • Implied Volatility 34.74% ( -0.82%)
  • Historical Volatility 19.82%
  • IV Percentile 86%
  • IV Rank 80.01%
  • IV High 38.67% on 10/26/23
  • IV Low 19.01% on 09/01/23
  • Put/Call Vol Ratio 0.81
  • Today's Volume 19,490
  • Volume Avg (30-Day) 28,468
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 255,249
  • Open Int (30-Day) 278,484

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 2.54
  • Number of Estimates 9
  • High Estimate 2.78
  • Low Estimate 2.34
  • Prior Year 1.62
  • Growth Rate Est. (year over year) +56.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
722.07 +3.27%
on 04/19/24
793.67 -6.05%
on 03/28/24
-24.92 (-3.23%)
since 03/22/24
3-Month
624.68 +19.37%
on 01/25/24
800.78 -6.88%
on 03/04/24
+116.01 (+18.42%)
since 01/23/24
52-Week
370.68 +101.17%
on 04/26/23
800.78 -6.88%
on 03/04/24
+360.45 (+93.57%)
since 04/21/23

Most Recent Stories

More News
Better Buy: Pfizer vs. Viking Therapeutics

These two pharma stocks have followed distinct paths of late. Which is the better investment?

LLY : 745.69 (+1.96%)
NVO : 128.64 (+2.70%)
NVDA : 824.23 (+3.65%)
AMGN : 273.54 (+0.60%)
PFE : 26.32 (+0.23%)
VKTX : 64.93 (+1.69%)
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential

Altimmune has a modest market cap but an incredibly promising GLP-1 drug.

LLY : 745.69 (+1.96%)
ALT : 7.57 (+1.34%)
3 Relatively Safe Growth Stocks You Can Buy and Hold

Low risk and high-reward potential? These stocks could offer both.

ALPN : 64.55 (-0.05%)
LLY : 745.69 (+1.96%)
NVO : 128.64 (+2.70%)
VRTX : 404.91 (+1.25%)
Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double

Structure Therapeutics is developing an oral weight-loss drug, which could allow it to gain traction in a rapidly expanding addressable market.

GPCR : 36.09 (+0.19%)
NVO : 128.64 (+2.70%)
LLY : 745.69 (+1.96%)
2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years

These stocks have taken different paths to where they are today, but both have been exceptional investments.

TSLA : 144.68 (+1.85%)
LLY : 745.69 (+1.96%)
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank

The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals.

NVO : 128.64 (+2.70%)
RMD.AX : 28.320 (+0.46%)
LLY : 745.69 (+1.96%)
RMD : 184.22 (+2.15%)
AHCO : 9.81 (+2.19%)
Stocks Give Up Early Gains on Weakness in Chip Stocks

The S&P 500 Index ($SPX ) (SPY ) this morning is down -0.22%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.16%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.55%. US stock indexes...

$SPX : 5,070.55 (+1.20%)
SPY : 505.65 (+1.19%)
$DOWI : 38,503.69 (+0.69%)
DIA : 385.02 (+0.69%)
$IUXX : 17,471.47 (+1.51%)
QQQ : 425.07 (+1.49%)
ZNM24 : 108-010 (-0.04%)
JBHT : 167.55 (+0.10%)
TRV : 214.32 (+0.02%)
ADSK : 217.93 (+0.37%)
ASML : 901.57 (+3.39%)
AMAT : 193.24 (+2.00%)
Stocks Rebound on Positive Q1 Earnings Results and Lower Bond Yields

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.42%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.33%. US stock indexes this morning...

$SPX : 5,070.55 (+1.20%)
SPY : 505.65 (+1.19%)
$DOWI : 38,503.69 (+0.69%)
DIA : 385.02 (+0.69%)
$IUXX : 17,471.47 (+1.51%)
QQQ : 425.07 (+1.49%)
ZNM24 : 108-010 (-0.04%)
UAL : 54.03 (+0.17%)
AAL : 14.23 (-2.06%)
DAL : 49.23 (+0.43%)
LUV : 29.46 (-0.91%)
AA : 36.06 (-0.80%)
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?

Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF?

LLY : 745.69 (+1.96%)
NVO : 128.64 (+2.70%)
BMY : 48.99 (-0.31%)
VOO : 464.84 (+1.26%)
Better Growth Play: Merck or The Vanguard Growth Index Fund?

Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?

LLY : 745.69 (+1.96%)
PFE : 26.32 (+0.23%)
BMY : 48.99 (-0.31%)
NVO : 128.64 (+2.70%)
GILD : 67.03 (+0.12%)
MRK : 126.88 (-0.05%)
VUG : 331.14 (+1.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 765.47
2nd Resistance Point 755.82
1st Resistance Point 750.75
Last Price 745.69
1st Support Level 736.03
2nd Support Level 726.38
3rd Support Level 721.31

See More

52-Week High 800.78
Last Price 745.69
Fibonacci 61.8% 636.48
Fibonacci 50% 585.73
Fibonacci 38.2% 534.98
52-Week Low 370.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar